Jasper Therapeutics appointed Patrick Crutcher as a director and named Matthew Ros Chief Operating Officer, both effective immediately after the Effective Time.
| IndividualPatrick CrutcherMatthew Ros | RoleClass I Director; member of Audit Committee and Nominating and Corporate Governance CommitteeChief Operating Officer | Type of ChangeAppointedAppointed | Effective DateImmediately after the Effective Time (July 16, 2026)Immediately after the Effective Time (July 16, 2026) | ReasonIn accordance with the Merger AgreementIn accordance with the Merger Agreement | Replacement InfoNot disclosedNot disclosed | Background Details15+ years building biotech companies; founder/chairman of multiple firms; prior CEO roles and company exits; B.S. Math (Univ. of Illinois), M.S./C.Phil. Statistics (UCLA)37+ years in pharma/biotech leadership; former COO of Verastem, prior CEO of Fore Biotherapeutics, senior roles at Epizyme, Sanofi, Genzyme; B.S. Business Administration (SUNY Plattsburgh) | Board/Committee Role ChangesAppointed to Audit Committee and Nominating and Corporate Governance CommitteeNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.